NovelMed Receives FDA IND Approval for NM8074 (Ruxoprubart), the First Anti-Bb Alternative Pathway Blocker for Treating Primary Immunoglobulin A Nephropathy (IgAN): A Renal Disorder
December 02, 2024 08:30 ET
|
NovelMed Therapeutics Inc
--- The United States FDA Clears Initiation of a Phase II Efficacy Trial in Immunoglobulin A Nephropathy (IgAN) Patients: a renal disorder Up to 50% of IgAN patients with persistent proteinuria...
Psychedelic Therapeutics Clinical Trials Research Report 2024 Featuring Yale University, Johnson & Johnson, Shire Pharmaceuticals, Pfizer, Lykos, and UCB
September 13, 2024 06:55 ET
|
Research and Markets
Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trials: Psychedelic Therapeutics" report has been added to ResearchAndMarkets.com's offering.This report provides a review of global...
Virtual Clinical Trials Market Analysis and Forecasts, 2024-2032: Technological Innovation and Patient-Centric Models Spearhead Industry Evolution
July 02, 2024 10:49 ET
|
Research and Markets
Dublin, July 02, 2024 (GLOBE NEWSWIRE) -- The "Virtual Clinical Trials Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and...
FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis (AAV) – a Chronic Rare Disease in Nephrology
June 17, 2024 08:30 ET
|
NovelMed Therapeutics Inc
-- The United States FDA Clears Initiation of Efficacy Trial in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Patients A Phase II, Efficacy Trial in adult AAV patients has...
$43+ Billion Cell and Gene Therapy Clinical Trials Market Forecast, 2024-2034, by Therapy Type, Phase, Indication, and Region
June 05, 2024 03:41 ET
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Clinical Trials Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's...
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
April 03, 2024 07:00 ET
|
Arch Biopartners
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an...
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
April 02, 2024 07:26 ET
|
Arch Biopartners
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have...
Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight Report 2024: Combining CDC7 Kinase Inhibitors with Existing Cancer Therapies for Enhanced Efficacy
January 11, 2024 05:28 ET
|
Research and Markets
Dublin, Jan. 11, 2024 (GLOBE NEWSWIRE) -- The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases
January 08, 2024 08:30 ET
|
NovelMed Therapeutics Inc
The USAN Council has officially adopted "Ruxoprubart (Ruk”soe proo' bart)" as the generic name for NM8074, marking a significant milestone in the drug development process.Ruxoprubart is an...
Over 15 ATR Protein Inhibitors in Clinical Trials, Signifying Significant Advancements in Cancer Pharmaceutical Research
November 09, 2023 06:43 ET
|
Research and Markets
Dublin, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The "Global ATR Protein Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering. A...